semaglutide and renal failure Effects of on Chronic Kidney Disease in Patients with Type 2 Diabetes Frontiers | Real-world use of

For weight management , semaglutide (Wegovy) is approved by the MHRA and has received a positive NICE technology appraisal recommendation for use in adults with obesity or overweight with weight-related comorbidities, subject to eligibility criteria

According to court filings, Novo Nordisk notified Hims of the patent and its alleged infringement and sent a letter on February 8, 2026, demanding that the company stop its unauthorized use of the technology

Microneedle patches are experimental : while research exists, none have FDA approval for delivering weight-loss peptides

Weight loss itself can lower HOMA-IR levels, although not to the extent seen in this study []